September 1, 2023
Now available ELREXFIO™
ELREXFIO™ (elranatamab-bcmm) injection, for subcutaneous use, is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Please see full prescribing information here.
PLEASE NOTE: To access these ELREXFIO products you must enroll and become certified in the ELREXFIO REMS.